Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2005

View Archived Issues

Antitumor activity and toxicity of new lamellarin analogues

New business strategy at Questcor

Abiogen's cell therapy starts phase I/II trial in peritoneal carcinosis

Pivotal phase II study of Lomucin in CF gets Irish go-ahead

Preclinical evaluation of genetically engineered interferon omega

Clinical evidence supports the use of Fibrillex in patients with amyloid A amyloidosis

Pep:trans demonstrates ability to transport drug across blood-brain barrier

NIAID grant supports influenza vaccine development efforts at AlphaVax

Salvat to file Cetraxal Otic in U.S.

Roche files sNDA for Tamiflu

FDA 510(k) clearance for Cumulase

PDUFA action date extended for Entereg NDA

Ortho-McNeil to acquire Peninsula Pharmaceuticals

Enrollment closed in phase II Cloretazine study in AML, MDS

Pre-IND meeting for phase II study of arimoclomol in ALS

Novel MCH-R1 antagonist synthesized and tested

Novel prodrug of BDCRB with improved bioavailability

TargeGen describes synthesis and development of PI3K inhibitor TG-100-115

New Aurora kinase inhibitor PHA-680632 presented at AACR meeting

Safer administration schedule identified for anticancer V-ATPase inhibitor

Celera Genomics identifies novel HDAC inhibitor with promising antitumor activity

Canadian approval for Sativex

AZD-0530: a novel antiinvasive cancer therapy targeting Src and Abl kinases

A phase II study reports on the effects of ularitide in congestive heart failure

Update on the weight effects of AOD-9604 in obese patients

Phase II data on the antitumor effects of BMS-184476 in advanced NSCLC

Novel antibacterial agents disclosed in recent patent literature

Vertex, Achillion report novel anti-HCV drugs

GlaxoSmithKline claims new compounds for the treatment of anemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...